Picture of SKAN AG logo

SKAN — SKAN AG News Story

0.000.00%
ch flag iconLast trade - 00:00
HealthcareBalancedMid CapHigh Flyer

Switzerland's SKAN Group H1 net sales rise on Services & Consumables growth, acquisitions

Switzerland's SKAN Group H1 net sales rise on Services & Consumables growth, acquisitions


Overview

  • Switzerland isolator systems maker's H1 net sales rose 22% yr/yr, driven by robust demand

  • Company returned to profit in H1, with net result of CHF 5.4 mln after prior-year loss

  • Profitability improved as project delays eased and Services & Consumables segment grew strongly


Outlook

  • SKAN confirms 2026 guidance: net sales to grow in high-teens percent range

  • Company expects 2026 EBITDA margin between 13% and 15%

  • SKAN sees robust demand but notes customers are prioritizing investments more selectively


Result Drivers

  • ACQUISITIONS - Consolidated acquisitions during the reporting period contributed to net sales growth

  • PROJECT DELAYS EASED - Profitability improved as prior-year project delays did not recur to the same extent and more projects were in high-value-added phases

  • SERVICES & CONSUMABLES SEGMENT - Strong growth in Services & Consumables, including acquisitions, boosted net sales and profitability


Company press release: ID:nEQ5jlbwDa


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

H1 Sales

CHF 164.48 mln

H1 EPS

CHF 0.21

H1 Net Income

CHF 5.45 mln

H1 Cash Flow from Operating Activities

CHF 16.32 mln

H1 EBIT

CHF 8.67 mln

H1 EBITDA

CHF 15.28 mln


Analyst Coverage

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"

  • The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

  • Wall Street's median 12-month price target for SKAN Group AG is CHF62.50, about 8.3% above its August 17 closing price of CHF57.70

  • The stock recently traded at 35 times the next 12-month earnings vs. a P/E of 30 three months ago


Reuters Recommended Reads

  • Aug 17 - Switzerland's Trifork Q2 revenue rises on Products segment growth, reiterates 2026 outlook

  • Aug 17 - Sandoz to license three biosimilar drugs from Shanghai Henlius Biotech

  • Aug 17 - Switzerland's HIAG Immobilien H1 net income jumps 90% on Chama condominium sales, revaluation gains


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on SKAN AG

See all news